🚀 VC round data is live in beta, check it out!
Avalon Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Avalon Pharma and similar public comparables like Alto Neuroscience, Medy-Tox, Zhejiang Shouxiangu, Neumora Therapeutics and more.
Avalon Pharma Overview
About Avalon Pharma
Middle East Pharmaceutical Industries Co is a holding company is engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments.
Founded
1998
HQ
Employees
541
Website
Sectors
Financials (FY)
EV
$619M
Avalon Pharma Financials
Avalon Pharma reported last fiscal year revenue of $105M and EBITDA of $28M.
In the same fiscal year, Avalon Pharma generated $65M in gross profit, $28M in EBITDA, and $21M in net income.
Revenue (LTM)
Avalon Pharma P&L
In the most recent fiscal year, Avalon Pharma reported revenue of $105M and EBITDA of $28M.
Avalon Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $105M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $65M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 62% | XXX | XXX | XXX |
| EBITDA | — | XXX | $28M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 24% | XXX | XXX | XXX |
| Net Profit | — | XXX | $21M | XXX | XXX | XXX |
| Net Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Debt | — | — | $11M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Avalon Pharma Stock Performance
Avalon Pharma has current market cap of $607M, and enterprise value of $619M.
Market Cap Evolution
Avalon Pharma's stock price is $30.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $619M | $607M | 0.0% | XXX | XXX | XXX | $1.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvalon Pharma Valuation Multiples
Avalon Pharma trades at 5.9x EV/Revenue multiple, and 22.5x EV/EBITDA.
EV / Revenue (LTM)
Avalon Pharma Financial Valuation Multiples
As of March 7, 2026, Avalon Pharma has market cap of $607M and EV of $619M.
Equity research analysts estimate Avalon Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avalon Pharma has a P/E ratio of 28.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $607M | XXX | $607M | XXX | XXX | XXX |
| EV (current) | $619M | XXX | $619M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 22.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 24.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.5x | XXX | XXX | XXX |
| P/E | — | XXX | 28.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 161.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avalon Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Avalon Pharma Margins & Growth Rates
Avalon Pharma's revenue in the last fiscal year grew by 16%.
Avalon Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 22% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Avalon Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alto Neuroscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| Neumora Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Design Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avalon Pharma M&A Activity
Avalon Pharma acquired XXX companies to date.
Last acquisition by Avalon Pharma was on XXXXXXXX, XXXXX. Avalon Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Avalon Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAvalon Pharma Investment Activity
Avalon Pharma invested in XXX companies to date.
Avalon Pharma made its latest investment on XXXXXXXX, XXXXX. Avalon Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Avalon Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avalon Pharma
| When was Avalon Pharma founded? | Avalon Pharma was founded in 1998. |
| Where is Avalon Pharma headquartered? | Avalon Pharma is headquartered in Saudi Arabia. |
| How many employees does Avalon Pharma have? | As of today, Avalon Pharma has over 541 employees. |
| Who is the CEO of Avalon Pharma? | Avalon Pharma's CEO is Mohammed Maher Al-Ghannam. |
| Is Avalon Pharma publicly listed? | Yes, Avalon Pharma is a public company listed on Tadawul. |
| What is the stock symbol of Avalon Pharma? | Avalon Pharma trades under 4016 ticker. |
| When did Avalon Pharma go public? | Avalon Pharma went public in 2024. |
| Who are competitors of Avalon Pharma? | Avalon Pharma main competitors are Alto Neuroscience, Medy-Tox, Zhejiang Shouxiangu, Neumora Therapeutics. |
| What is the current market cap of Avalon Pharma? | Avalon Pharma's current market cap is $607M. |
| What is the current revenue of Avalon Pharma? | Avalon Pharma's last fiscal year revenue is $105M. |
| What is the current EV/Revenue multiple of Avalon Pharma? | Current revenue multiple of Avalon Pharma is 5.9x. |
| Is Avalon Pharma profitable? | No, Avalon Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.